Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of otilimab in rheumatoid arthritis
jRCT2080225238Phase 3Completed
- Sponsor
- GSK
- Start
- Jun 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, open-label trial of otilimab in rheumatoid arthritis (RA) (2 arms), sponsored by GSK. Primary endpoints: Incidence of adverse events (AEs), Incidence of serious adverse events (SAEs) and 1 more. Started Jun 2020; status: completed.
02
Drugs
otilimab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on jRCT2080225238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225238.